Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 20/20 | 0.69 |
| ▸ | CDK6 | Q00534 | 14/20 | 0.69 |
| ▸ | CDK2 | P24941 | 13/20 | 0.69 |
| ▸ | CDK1 | P06493 | 13/20 | 0.65 |
| ▸ | CDK7 | P50613 | 5/20 | 0.65 |
| ▸ | CDK9 | P50750 | 5/20 | 0.65 |
| ▸ | CCNB1 | P14635 | 9/20 | 0.65 |
| ▸ | CCNE1 | P24864 | 9/20 | 0.65 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.62 |
| ▸ | CCND3 | P30281 | 2/20 | 0.62 |
| ▸ | CIT | O14578 | 1/20 | 0.62 |
| ▸ | GAK | O14976 | 1/20 | 0.62 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.62 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.62 |
| ▸ | STK16 | O75716 | 1/20 | 0.62 |
| ▸ | CCNK | O75909 | 1/20 | 0.62 |
| ▸ | STK10 | O94804 | 1/20 | 0.62 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.62 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.62 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15252340 | 0.95 | CDK4 (0.65) | CDK4CDK6CDK2CDK1CDK7 | |
| SCHEMBL19220707 | 0.94 | CDK4 (0.62) | CDK4CDK6CDK2CDK1CDK7 | |
| SCHEMBL3446950 | 0.90 | CDK4 (0.62) | CDK4CDK6CDK2CDK1CDK7 | |
| SCHEMBL17488826 | 0.88 | CDK4 (0.67) | CDK4CDK6CDK2CDK1CDK7 | |
| SCHEMBL3447392 | 0.88 | CDK4 (0.62) | CDK4CDK6CDK2CDK1CDK7 | |
| SCHEMBL19225629 | 0.87 | CDK4 (0.69) | CDK4CDK6CDK2CDK1CDK7 | |
| SCHEMBL13012342 | 0.86 | CDK4 (0.60) | CDK4CDK6CDK2CDK1CDK7 | |
| SCHEMBL19968048 | 0.86 | CDK4 (0.68) | CDK4CDK6CDK2CDK1CDK7 | |
| SCHEMBL13012327 | 0.85 | CDK4 (0.67) | CDK4CDK6CDK2CDK1CDK7 | |
| SCHEMBL15252458 | 0.84 | CDK4 (0.58) | CDK4CDK6CDK2CDK1CDK7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170224819-A1 | Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor, a JAK-2 Inhibitor, and/or a CDK 4/6 Inhibitor | ACERTA PHARMA BV (NL) | 2017-08-10 | — | — | US | disclosed |
| EP-2379528-B1 | PROTEIN KINASE INHIBITORS | LILLY CO ELI (US) | 2013-09-18 | — | — | EP | disclosed |
| EP-2379528-B1 | PROTEIN KINASE INHIBITORS | LILLY CO ELI (US) | 2013-09-18 | — | — | EP | disclosed |
| US-7855211-B2 | such as [5-(4-Ethyl-piperazin-1-ylmethyl)-pyridin-2-yl]-[5-fluoro-4-(7-fluoro-3-isopropyl-2-methyl-3H-benzoimidazol-5-yl)-pyrimidin-2-yl]-amine, useful in the treatment of cell proliferative diseases | ELI LILLY AND COMPANY (US) | 2010-12-21 | — | — | US | disclosed |
| US-7855211-B2 | such as [5-(4-Ethyl-piperazin-1-ylmethyl)-pyridin-2-yl]-[5-fluoro-4-(7-fluoro-3-isopropyl-2-methyl-3H-benzoimidazol-5-yl)-pyrimidin-2-yl]-amine, useful in the treatment of cell proliferative diseases | ELI LILLY AND COMPANY (US) | 2010-12-21 | — | — | US | disclosed |
| US-7855211-B2 | such as [5-(4-Ethyl-piperazin-1-ylmethyl)-pyridin-2-yl]-[5-fluoro-4-(7-fluoro-3-isopropyl-2-methyl-3H-benzoimidazol-5-yl)-pyrimidin-2-yl]-amine, useful in the treatment of cell proliferative diseases | ELI LILLY AND COMPANY (US) | 2010-12-21 | — | — | US | disclosed |
| WO-2010075074-A1 | PROTEIN KINASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2010-07-01 | — | — | WO | disclosed |
| US-20100160340-A1 | such as [5-(4-Ethyl-piperazin-1-ylmethyl)-pyridin-2-yl]-[5-fluoro-4-(7-fluoro-3-isopropyl-2-methyl-3H-benzoimidazol-5-yl)-pyrimidin-2-yl]-amine, useful in the treatment of cell proliferative diseases | ELI LILLY AND COMPANY | 2010-06-24 | — | — | US | disclosed |
| US-20100160340-A1 | such as [5-(4-Ethyl-piperazin-1-ylmethyl)-pyridin-2-yl]-[5-fluoro-4-(7-fluoro-3-isopropyl-2-methyl-3H-benzoimidazol-5-yl)-pyrimidin-2-yl]-amine, useful in the treatment of cell proliferative diseases | ELI LILLY AND COMPANY | 2010-06-24 | — | — | US | disclosed |
| US-20100160340-A1 | such as [5-(4-Ethyl-piperazin-1-ylmethyl)-pyridin-2-yl]-[5-fluoro-4-(7-fluoro-3-isopropyl-2-methyl-3H-benzoimidazol-5-yl)-pyrimidin-2-yl]-amine, useful in the treatment of cell proliferative diseases | ELI LILLY AND COMPANY | 2010-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160340-A1 | such as [5-(4-Ethyl-piperazin-1-ylmethyl)-pyridin-2-yl]-[5-fluoro-4-(7-fluoro-3-isopropyl-2-methyl-3H-benzoimidazol-5-yl)-pyrimidin-2-yl]-amine, useful in the treatment of cell proliferative diseases | MKI67, PKD1, CCNI | CDK4 26/4885CDK6 86/4885CDK2 47/4885 |
| US-20170224819-A1 | Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor, a JAK-2 Inhibitor, and/or a CDK 4/6 Inhibitor | BTK, CDK6, CDK4 | CDK4 3/4885CDK6 2/4885CDK2 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.